Funding momentum Rapafusyn has secured a $44M Series A and ongoing funding activity, signaling readiness to scale partnerships, clinical programs, and collaboration opportunities with companies seeking innovative drug discovery and development capabilities.

Targeted opportunities The focus on non-degrading molecular glue therapeutics positions Rapafusyn to partner with biotech and pharma companies pursuing targeted protein degradation strategies, offering collaboration on discovery, optimization, or translational studies.

Strategic collaborations Regular engagement at industry events and roundtables (WuXi Global Forum, investment conferences, and protein degradation summits) indicates openness to co-development models, licensing discussions, and joint research programs.

Academic tech access Licensed technology from Johns Hopkins University School of Medicine suggests potential for academia-industry partnerships, technology commercialization deals, and joint IP-rich programs with early-stage discovery platforms.

Geographic focus Based in Baltimore with activity at national and international conferences, Rapafusyn is well-positioned for U.S. market collaborations and cross-border partnerships with sponsors and CROs seeking specialized molecular glue capabilities.